www.onkologiecs.cz ONKOLOGIE 79 MONOKLONÁLNÍ GAMAPATIE PŘEHLED PŘÍNOSU DARATUMUMABU PRO LÉČBU VŠECH MONOKLONÁLNÍCH GAMAPATIÍ, ALE I DALŠÍCH NEMOCÍ A VLASTNÍ ZKUŠENOSTI S LÉČBOU 74 PACIENTŮ DARATUMUMABEM, LENALIDOMIDEM A DEXAMETAZONEM of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020;7(12):e874-e883. doi: 10.1016/S23523026(20)30356-2. 84. Hulin C, Offner F, Moreau P, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/ thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica. 2021;106(8):2257-2260. doi: 10.3324/ haematol.2020.261842. 85. Mohyuddin GR, Mian H. Daratumumab in newly diagnosed MM – incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol. 2022;19(1):3-4. doi: 10.1038/s41571-021-00581-2. 86. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dex- amethasone for untreated myeloma. N Engl J Med. 2019;380:2104-2115 . 87. Jain A, Ramasamy K. Evolving Role of Daratumumab: From Backbencher to Frontline Agent. Clin Lymphoma Myeloma Leuk. 2020;20(9):572-587. doi:10.1016/j.clml.2020.03.010. 88. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, openlabel, phase 3 trial. Lancet Oncol. 2021;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. 89. Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066-1077. doi: 10.1038/ s41375-021-01488-8. 90. Faith D, Rifkin R, Costelo C, Hájek R. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Annals of hematology. 2021;100(9):2325-2337. 91. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone fortransplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936-945. doi: 10.1182/ blood.2020005288. 92. Voorhees PM, Rodriguez C, Reeves B, et al. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021;5(4):1092-1096. doi:10.1182/bloodadvances.2020003642. 93. Nooka AK, Kaufman JL, Rodriguez C, et al. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022;12(4):63. doi: 10.1038/ s41408-022-00653-1. 94. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Br J Haematol. 2019;185(3):492-502. doi: 10.1111/bjh.15806. 95. Yimer H, Melear J, Faber E, et al. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Leuk Lymphoma. 2022:1-10. doi: 10.1080/10428194.2022.2076847. 96. Landgren O, Hultcrantz M, Diamond B, et al. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial. JAMA Oncol. 2021;7(6):862-868. doi: 10.1001/jamaoncol.2021.0611. 97. Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021 Dec 13:JCO2101935. doi 10.1200/JCO.21.01935. 98. NCCN Guidelines Version 4.2022, Multiple Myeloma, https://www.nccn.org/ professionals/physician _ gls/pdf/ myeloma.pdf. Accessed 1.22.2022. 99. Giri S, Grimshaw A, Bal S. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With Highrisk Cytogenetic Factors: A Systematic Review and Metaanalysis. JAMA Oncol. 2020;6(11):1759-1765. doi: 10.1001/jamaoncol.2020.4338. 100. Weisel K, Spencer A, Lentzsch S, et al. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol. 2020;13(1):115-120. doi: 10.1186/s13045-020-00948-5. 101. Jakubowiak AJ, Kumar S, Medhekar R, et al. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 Apr 24:oyac067. doi: 10.1093/oncolo/oyac067. 102. Kaufman JL, Dimopoulos MA, White D, et al. Daratumumab, lenalidomide, and dexamethasone in relapsed/ refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer J. 2020 Nov 3;10(11):111. doi: 10.1038/ s41408-020-00375-2. 103. Wang Y, Li Y, Chai Y. Efficacy and safety of daratumumab in the treatment of multiplemyeloma: a systematic review and meta-analysis. J Int Med Res. 2021;49 (8):3000605211038135. doi: 10.1177/03000605211038135. 104. Landgren O, Weisel K, Rosinol L, et al. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18233. 105. Rene CG, Achiam MP, Salomo M, et al. Extramedullary relapse in a patient with multiple myeloma: a rare cause of gastrointestinal perforation and massive bleeding. BMJ Case Rep. 2021;14(11):e243663. doi:10.1136/bcr-2021-243663. 106. Uslu A, Seval GC, Merter M. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review. Clin Lymphoma Myeloma Leuk. 2021;21(3):e267-e271. doi: 10.1016/j. clml.2020.11.017. 107. Mohamed M, Alhillan A, Gupta V, Nahum K, et al. Relapsing Cutaneous Multiple Myeloma Responding to Immunochemotherapy: A Rare Case Report. J Med Cases. 2019;10(10):305-308. doi: 10.14740/jmc3382. 108. Gozzetti A, Cerase A, Bocchia M. Daratumumab efficacy in extramedullary orbital myeloma. Clin Case Rep. 2020;8(12): 3652-3653. doi: 10.1002/ccr3.3458. 109. Moreno DF, Clapés V, Soler JA, et al. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clin Lymphoma Myeloma Leuk. 2022 Apr 17: S21522650(22)00126-4. doi: 10.1016/j.clml.2022.04.014. 110. Jelínek T, Ševčíková T, Žihala D, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36(1):288-291. 111. Jelínek T, Maisnar V, Pour L, et al. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients. Current medical research and opinion. 2018;34(5):775-783. 112. Harvanová Ľ, Štulajterová V, Guman T, et al. A. Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia. Neoplasma. 2021;68(3):626-630. doi: 10.4149/ neo_2021_201113N1223. 113. Vela-Ojeda J, Gómez-Almaguer D, Espinoza-Zamora R, et al. Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico. Arch Med Res. 2021;52(6):627634. doi: 10.1016/j.arcmed.2021.02.008. 114. Pick M, Vainstein V, Goldschmidt N, et al. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis. Eur J Haematol. 2018;100(5):494-501. doi: 10.1111/ejh.13046. 115. Zajec M, Frerichs KA, van Duijn MM, et al. Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma. Hemasphere. 2020;4(4):e413. doi: 10.1097/ HS9.0000000000000413. 116. Elhassadi E, Murphy M, Hacking D, et al. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. Clin Case Rep. 2018;6(4):723-728. doi: 10.1002/ccr3.1451. 117. Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program. 2020;(1):380-388. doi: 10.1182/hematology.2020000122. 118. Lecumberri R, Krsnik I, Askari E, et al. Treatment with daratumumab in pa tients with relapsed/refractory AL amyloidosis: A multicentric retrospective study and review of the literature. Amyloid. 2020;27(3):163-167. 119. Roussel M, Merlini G, Chevret S, et al. A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis (AL) patients. Blood. 2020;135:1531. 120. Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020;135(18):1541-1547. doi: 10.1182/blood.2019004436. 121. Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):7180. doi:10.1182/blood.2019004460. 122. Kastritis E, Palladini G, Minnema MC, et al. ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021;385(1):46-58. doi: 10.1056/NEJMoa2028631. 123. Sanchorawala V, Palladini G, Minnema MC, et al. Healthrelated quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone±daratumumab: Results from the ANDROMEDA study. Am J Hematol. 2022;97(6):719-730. doi: 10.1002/ajh.26536. 124. Kaufman GP, Cerchione C. Beyond Andromeda: Improving Therapy for Light Chain Amyloidosis. Front Oncol. 2021;10:624573. doi: 10.3389/fonc.2020.624573. 125. Theodorakakou F, Dimopoulos MA, Kastritis E. Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis. Ther Adv Hematol. 2021;12: 20406207211058334. doi: 10.1177/20406207211058334. 126. Janssen Biotech Darzalex+Faspro (daratumumab and hyaluronidase- fihj)[package insert]. U.S. food and drug administration. Accessed from: https: //www.janssenlabels. com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf. 2022; 20 January. 127. Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020;135(18):15171530. doi: 10.1182/blood.2019003633. 128. Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Am J Hematol. 2020;95(8):900-905. doi: 10.1002/ajh.25828. 129. Sammartano V, Antonioli E, Buda G, et al. Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network). J Pers Med. 2022 Mar 17;12(3):484. doi: 10.3390/jpm12030484. PMID: 35330483; PMCID: PMC8952680. 130. Mar E, Taylor K, Mollee P. Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding. BMJ Case Rep. 2021;14(4):e240631. 131. Chaulagain CP, Herlitz LC, Fu J, et al. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). Clin Lymphoma Myeloma Leuk. 2020;20(11):e826-e831. doi: 10.1016/j.clml.2020.06.017. 132. Shimamura Y, Ogawa Y, Takizawa H, et al. Light Chain Deposition Disease Diagnosed Using Computed Tomography-Guided Kidney Biopsy. Cureus. 2021;13(5):e15102. doi: 10.7759/cureus.15102. 133. Kastritis E, Rousakis P, Kostopoulos IV, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosisor light chain deposition disease. Amyloid.
RkJQdWJsaXNoZXIy NDA4Mjc=